Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12119421 | 0.87 | ALDH1A1 (0.41) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL25779341 | 0.84 | KDM4E (0.39) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL22167732 | 0.82 | LMNA (0.37) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL24089553 | 0.81 | KDM4E (0.40) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL14778772 | 0.81 | ALDH1A1 (0.43) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL26465758 | 0.80 | KDM4E (0.44) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL13079446 | 0.78 | KDM4E (0.34) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL25779313 | 0.78 | TDP1 (0.48) | LMNAALDH1A1TSHRTDP1 | |
| SCHEMBL25779352 | 0.76 | KDM4E (0.44) | LMNAKDM4EUSP2ALDH1A1MMP9 | |
| SCHEMBL25779334 | 0.76 | KDM4E (0.48) | LMNAKDM4EUSP2ALDH1A1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | RPN2, MPDU1, RPN1 | LMNA 2253/4885KDM4E 3528/4885USP2 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.